Cargando…
High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435777/ https://www.ncbi.nlm.nih.gov/pubmed/34527580 http://dx.doi.org/10.3389/fonc.2021.701492 |
_version_ | 1783751869710991360 |
---|---|
author | Li, Philippa Yuan, Ji Ahmed, Fahad Shabbir McHenry, Austin Fu, Kai Yu, Guohua Cheng, Hongxia Xu, Mina L. Rimm, David L. Pan, Zenggang |
author_facet | Li, Philippa Yuan, Ji Ahmed, Fahad Shabbir McHenry, Austin Fu, Kai Yu, Guohua Cheng, Hongxia Xu, Mina L. Rimm, David L. Pan, Zenggang |
author_sort | Li, Philippa |
collection | PubMed |
description | BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse large B-cell lymphomas (DLBCL). While mantle cell lymphoma (MCL) is well-known to contain frequent epithelioid macrophages, LAM characterization within MCL has not been fully described. Herein we evaluate the immunophenotypic subclassification, the expression of immune checkpoint molecule PD-L1, and the prognostic impact of LAMs in MCL. MATERIALS AND METHODS: A total of 82 MCL cases were collected and a tissue microarray block was constructed. Immunohistochemical staining was performed using CD68 and CD163, and the positive cells were recorded manually in four representative 400× fields for each case. Multiplexed quantitative immunofluorescence assays were carried out to determine PD-L1 expression on CD68+ M1 LAMs and CD163+ M2 LAMs. In addition, we assessed Ki67 proliferation rate of MCL by an automated method using the QuPath digital imaging analysis. The cut-off points of optimal separation of overall survival (OS) were analyzed using the X-Tile software, the SPSS version 26 was used to construct survival curves, and the log-rank test was performed to calculate the p-values. RESULTS: MCL had a much higher count of M1 LAMs than M2 LAMs with a CD68:CD163 ratio of 3:1. Both M1 and M2 LAMs were increased in MCL cases with high Ki67 proliferation rates (>30%), in contrast to those with low Ki67 (<30%). Increased number of M1 or M2 LAMs in MCL was associated with an inferior OS. Moreover, high expression of PD-L1 on M1 LAMs had a slightly better OS than the cases with low PD-L1 expression, whereas low expression of PD-L1 on M2 LAMs had a slightly improved OS, although both were not statistically significant. CONCLUSIONS: In contrast to DLBCL, MCL had a significantly lower rate of M1 to M2 polarization, and the high levels of M1 and M2 LAMs were associated with poor OS. Furthermore, differential PD-L1 expressions on LAMs may partially explain the different functions of tumor-suppressing or tumor-promoting of M1 and M2 LAMs, respectively. |
format | Online Article Text |
id | pubmed-8435777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84357772021-09-14 High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis Li, Philippa Yuan, Ji Ahmed, Fahad Shabbir McHenry, Austin Fu, Kai Yu, Guohua Cheng, Hongxia Xu, Mina L. Rimm, David L. Pan, Zenggang Front Oncol Oncology BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse large B-cell lymphomas (DLBCL). While mantle cell lymphoma (MCL) is well-known to contain frequent epithelioid macrophages, LAM characterization within MCL has not been fully described. Herein we evaluate the immunophenotypic subclassification, the expression of immune checkpoint molecule PD-L1, and the prognostic impact of LAMs in MCL. MATERIALS AND METHODS: A total of 82 MCL cases were collected and a tissue microarray block was constructed. Immunohistochemical staining was performed using CD68 and CD163, and the positive cells were recorded manually in four representative 400× fields for each case. Multiplexed quantitative immunofluorescence assays were carried out to determine PD-L1 expression on CD68+ M1 LAMs and CD163+ M2 LAMs. In addition, we assessed Ki67 proliferation rate of MCL by an automated method using the QuPath digital imaging analysis. The cut-off points of optimal separation of overall survival (OS) were analyzed using the X-Tile software, the SPSS version 26 was used to construct survival curves, and the log-rank test was performed to calculate the p-values. RESULTS: MCL had a much higher count of M1 LAMs than M2 LAMs with a CD68:CD163 ratio of 3:1. Both M1 and M2 LAMs were increased in MCL cases with high Ki67 proliferation rates (>30%), in contrast to those with low Ki67 (<30%). Increased number of M1 or M2 LAMs in MCL was associated with an inferior OS. Moreover, high expression of PD-L1 on M1 LAMs had a slightly better OS than the cases with low PD-L1 expression, whereas low expression of PD-L1 on M2 LAMs had a slightly improved OS, although both were not statistically significant. CONCLUSIONS: In contrast to DLBCL, MCL had a significantly lower rate of M1 to M2 polarization, and the high levels of M1 and M2 LAMs were associated with poor OS. Furthermore, differential PD-L1 expressions on LAMs may partially explain the different functions of tumor-suppressing or tumor-promoting of M1 and M2 LAMs, respectively. Frontiers Media S.A. 2021-08-30 /pmc/articles/PMC8435777/ /pubmed/34527580 http://dx.doi.org/10.3389/fonc.2021.701492 Text en Copyright © 2021 Li, Yuan, Ahmed, McHenry, Fu, Yu, Cheng, Xu, Rimm and Pan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Li, Philippa Yuan, Ji Ahmed, Fahad Shabbir McHenry, Austin Fu, Kai Yu, Guohua Cheng, Hongxia Xu, Mina L. Rimm, David L. Pan, Zenggang High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis |
title | High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis |
title_full | High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis |
title_fullStr | High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis |
title_full_unstemmed | High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis |
title_short | High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis |
title_sort | high counts of cd68+ and cd163+ macrophages in mantle cell lymphoma are associated with inferior prognosis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435777/ https://www.ncbi.nlm.nih.gov/pubmed/34527580 http://dx.doi.org/10.3389/fonc.2021.701492 |
work_keys_str_mv | AT liphilippa highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT yuanji highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT ahmedfahadshabbir highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT mchenryaustin highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT fukai highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT yuguohua highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT chenghongxia highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT xuminal highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT rimmdavidl highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis AT panzenggang highcountsofcd68andcd163macrophagesinmantlecelllymphomaareassociatedwithinferiorprognosis |